drugset
drugset / Trial / NCT07231068

A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

NCT07231068 ↗

Phase 1/2 Recruiting 153 enrolled Henan Genuine Biotech Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

This is an open label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy of Dositinib in participants of locally advanced or metastatic non-small cell lung cancer with positive EGFR mutation.

Timeline

Start
2022-10-31
Primary completion
2027-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dositinib Small molecule 20 mg Oral
Subject Dositinib Small molecule 40 mg Oral
Subject Dositinib Small molecule 80 mg Oral
Subject Dositinib Small molecule 160 mg Oral
Subject Dositinib Small molecule 200 mg Oral
Subject Dositinib Small molecule 240 mg Oral

Indications

non-small cell lung carcinoma